Anatara announces exclusive global license agreement with Zoetis
Anatara Lifesciences announced an exclusive licensing agreement with Zoetis for the worldwide development, manufacture, distribution and marketing of Detach as a non-antibiotic approach to aid in the control of diarrhoeal disease in livestock and in horses. Under the terms of the license agreement, Anatara has granted Zoetis exclusive rights to develop, manufacture, distribute and market Detach worldwide, including in Australia. The agreement follows an initial Exclusive Research Evaluation and License Option period, during which time Zoetis evaluated Detach for use as a non-antibiotic product in livestock species. The terms of the agreement include an upfront payment, milestone payments and royalties based on product sales. Intellectual property exclusively licensed to Zoetis under the agreement shall remain the sole property of Anatara. Exact details of the agreement remain confidential.